Mar 23, 2020
Understanding What Is Considered a “Significant” Change Under EU MDR Article 120(3) and MDCG 2020-3
The EU MDR imposes strict requirements on medical device companies marketing their products in Europe. Many device companies scrambled to renew existing CE certificates granted under the old Medical Devices Directive, allowing them to sell that device in Europe until those certificates expire or May 2024, whichever comes first.
Whatever the reason, companies need to be careful to make sure they do not make significant changes that would raise the ire of Notified Bodies and trigger a mandatory new EU MDR registration, or risk having to prematurely pull their product from the EU market.
Letâs consider an example.
Suppose you renewed an existing MDD certificate on April 2, 2020 and it expires on April 1, 2023. What if you want/need to make changes to the device? Well, you have two options:
- Pull the device off the market while you pursue CE certification under the EU MDR.
- Determine if the change is considered âsignificantâ and, if it is not, secure a derogation (permission) from your Notified Body to make the change.
A Strong Need to Define âSignificantâ
Hereâs an excerpt from Article 120 of the MDR, which we have shortened for clarity:
âBy way of derogationâ¦a device with a certificate that was issued in accordance with Directive 90/385/EEC or Directive 93/42/EECâ¦may only be placed on the market â¦ provided there are no significant changes in the design and intended purpose.âÂ
Ok, this would seem to indicate that only changes to the device design and intended purpose count as âsignificant.â Thatâs not really true. (Weâll get to that in a minute.) After the EU MDR was published, various industry groups understood that manufacturers might, shall we say, apply liberal interpretations of the word âsignificant.â As such industry has been clamoring for official guidance that would add more specificity to Article 120. The Medical Device Coordination Group (MDCG) finally did so in releasing MDCG 2020-3. The main content of this document is contained in five decision trees focused on key areas of change:
Examples of Changes Outlined in MDCG 2020-3 That May Be Considered âSignificantâ Under Article 120(3)
Here are some (but not all) common examples of changes that may be considered significant according to the guidance. Please study the guidance and consult with your Notified Body as their opinion may differ from yours.
Chart A – Intended Purpose
- Extension or change to the intended purpose
- New user or patient population
- Change of clinical use (example: anatomical site)
Chart B â Design or Performance Specification
- Requires further clinical or usability data
- New risks require control measures
- Existing risks negatively affected
- Change to built-in control mechanism
- Change to operating principles, source of energy or alarms
Chart C â Software
- New or major change to operating system or component
- New/modified architecture/database structure
- Change of algorithm (but not software bug fixes, security updates)
- Required user input replaced by closed loop algorithm
- New diagnostic or therapeutic features or new channel of interoperability
- New user interface or presentation of data that impacts performance
Chart D â Materials
- Change of material of human/animal origin, including addition of new materials
- Change to material containing a medicinal substance, or the substance itself
- Manufacturing or other change that may impact quality, safety or efficacy of a medicinal substance
- Ingredient or material from new supplier does not meet existing specification
Chart E â Sterilization/Packaging
- Change to terminal sterilization method
- Design change that affects or changes sterility assurance
- Packaging design change affects functionality, safety, stability or seal integrity
- Shelf life change not validated by protocols approved by Notified Body
Again this is not a complete list so be sure to download MDCG 2020-3.
Changes to Your QMS Can Count as âSignificantâ as Well!
âSignificantâ changes are not limited to changes in design and intended purpose. While most of the guidance focuses on changes to the device, materials, or its intended purpose, those are not the only changes a Notified Body may see as significant enough to invalidate an MDD CE certificate. Section 9.6 of this document issued by the International Accreditation Forum (IAF) in June 2017 discusses QMS changes that Notified Bodies may consider significant. They include:
- Change in company ownership
- Extension to manufacturing and/or design control
- New facility or line modification/relocation
- Significant modifications to special processes
- Change in authority of the management representative
- Postmarket surveillance and vigilance issues
- Concerns about implementation or corrective actions
Here are some common examples of changes that could be deemed significant:
- Making an insignificant design change to mitigate risks discovered during postmarket surveillance may constitute a significant change for that product.
- Changing the floorplan of a manufacturing facility, especially for processes considered âspecialâ or critical to the product. This could be considered a significant change, and it may require that the change be implemented in compliance with the regulations.
- A manufacturer consolidates or centralizes a key system of their QMS (e.g., design control) across multiple sites.
Be Mindful of Changes and Their Impact
Manufacturers looking to extend the life of their MDD CE certification should always be mindful of the fact that Notified Body auditors will be examining their devices and processes through the lens of the EU MDR and ISO 13485:2016. Understanding which changes are allowable is critical before actually making them. When in doubt, talk to your Notified Body before considering any changes.
Want to Learn More?
We have two training classes that may interest you. This intensive training class on medical device design control gives you an in-depth look at how to properly structure your QMS processes and manage changes.Â Our popular EU MDR auditor training class is also an excellent deep dive into all facets of 2017/745. Of course, our EU MDR consulting team remains at your service to answer questions about what is (and is not) a âsignificantâ change.
Our team is here to help. Contact us online
Get answers right now. Call
US OfficeWashington DC
EU OfficeCork, Ireland